USPTO Trademark Application: TRIPTODUR CARE
Summary
The USPTO has received an Intent to Use trademark application (TM99167826) for the mark 'TRIPTODUR CARE'. The application covers services related to patient support, financial assistance for medication reimbursement, and medical information for endocrine disorders.
What changed
The United States Patent and Trademark Office (USPTO) has recorded an Intent to Use trademark application for 'TRIPTODUR CARE' (Application No. 99167826). The application, filed on May 2, 2025, seeks to protect services including patient support, emotional counseling, financial assistance for medication reimbursement programs, and the provision of medical information related to hormonal and endocrine disorders, specifically for treatments concerning precocious puberty.
This filing indicates a potential future offering of services related to pharmaceutical access and patient assistance programs. While this is a trademark application and not a regulatory rule, companies operating in the pharmaceutical and patient support sectors should be aware of the mark's potential use and scope. No immediate compliance actions are required for other entities based on this filing, but it may signal future market activity or branding efforts by the applicant.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
← USPTO Trademark Applications
TRIPTODUR CARE
Intent to Use TM99167826 Kind: intenttouse Mar 20, 2026
Abstract
Providing information relating to patient support services in the nature of personal support services for patients, namely, emotional counseling and emotional support; Providing information relating to business administration guidance in the field of medication reimbursement programs and services; Providing information relating to patient support services in the nature of providing financial support to patients for the purpose of facilitating good health and affordability programs being financial administration of patient reimbursement programs, drug access, and financial administration guidance in the nature of medication reimbursement programs and services; Providing medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, in the nature of affordability programs being patient assistance programs to provide medicines at low or no cost to patients undergoing treatment for central precocious puberty, medicine access, and administration guidance
Filing Date
2025-05-02
Related changes
Get daily alerts for USPTO Trademarks - Legal & Security (Class 045)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Trademarks - Legal & Security (Class 045) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.